1. Home
  2. CYTK vs CNO Comparison

CYTK vs CNO Comparison

Compare CYTK & CNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • CNO
  • Stock Information
  • Founded
  • CYTK 1997
  • CNO 1979
  • Country
  • CYTK United States
  • CNO United States
  • Employees
  • CYTK N/A
  • CNO N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • CNO Accident &Health Insurance
  • Sector
  • CYTK Health Care
  • CNO Finance
  • Exchange
  • CYTK Nasdaq
  • CNO Nasdaq
  • Market Cap
  • CYTK 4.6B
  • CNO 3.8B
  • IPO Year
  • CYTK 2004
  • CNO 1987
  • Fundamental
  • Price
  • CYTK $60.16
  • CNO $41.25
  • Analyst Decision
  • CYTK Strong Buy
  • CNO Hold
  • Analyst Count
  • CYTK 15
  • CNO 5
  • Target Price
  • CYTK $76.73
  • CNO $43.60
  • AVG Volume (30 Days)
  • CYTK 1.7M
  • CNO 554.9K
  • Earning Date
  • CYTK 11-05-2025
  • CNO 11-03-2025
  • Dividend Yield
  • CYTK N/A
  • CNO 1.65%
  • EPS Growth
  • CYTK N/A
  • CNO 20.08
  • EPS
  • CYTK N/A
  • CNO 2.98
  • Revenue
  • CYTK $87,211,000.00
  • CNO $4,441,500,000.00
  • Revenue This Year
  • CYTK $363.61
  • CNO N/A
  • Revenue Next Year
  • CYTK $64.33
  • CNO $3.27
  • P/E Ratio
  • CYTK N/A
  • CNO $13.84
  • Revenue Growth
  • CYTK 2609.26
  • CNO N/A
  • 52 Week Low
  • CYTK $29.31
  • CNO $34.63
  • 52 Week High
  • CYTK $64.13
  • CNO $43.20
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 55.21
  • CNO 59.35
  • Support Level
  • CYTK $58.05
  • CNO $39.19
  • Resistance Level
  • CYTK $61.29
  • CNO $42.00
  • Average True Range (ATR)
  • CYTK 2.60
  • CNO 0.87
  • MACD
  • CYTK -0.48
  • CNO 0.08
  • Stochastic Oscillator
  • CYTK 57.88
  • CNO 66.61

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About CNO CNO Financial Group Inc.

CNO Financial Group Inc is a holding company for a group of insurance companies that offers middle-income American consumers insurance and securities products through exclusive agents, independent producers, and direct marketing. Consumers are served through the phone, online, mail, face-to-face with agents, or sales channels. The company's operating segments include annuity, health, and life insurance product lines as well as the investment and fee revenue segments. Maximum revenue is generated from the health product line segment. Annuity premiums account for the majority of the total premiums collected. Annuity products include fixed index annuities, traditional fixed-rate annuities, and single-premium immediate annuity products.

Share on Social Networks: